Adding docetaxel-based chemotherapy to standard treatment for high-risk prostate cancer

(NRG Oncology) Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news